Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Thymoglobulin dosing in pediatric hematopoietic cell transplantation
NL-OMON47267Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2015
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin in Condition requiring hematopoietic cell transplantation, sponsored by University Medical Center Utrecht. Primary endpoint: CD4+ T-cell immune reconstitution within 100 days. Started Jun 2015; status: active, not recruiting.
02
Drugs
antithymocyte globulin
03
Conditions
Condition requiring hematopoietic cell transplantation
Beyond the preview
Go deeper on NL-OMON47267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47267.